Details of Disease

General Information of Disease (ID: DIS9XD9A)

Disease Name	Hematologic disease
Synonyms	haematological disorders and malignancies; hematological disorders and malignancies; hematological disease; disorder of haematopoietic system; rare hematologic disease; haematopoietic system disease; haematopoietic system disease or disorder; hematologic and lymphocytic disorder; blood disease; hematologic disorder; hematopoietic system disease or disorder; hematological system disease; haematological disorder; disease of the blood and blood-forming organs; haematological system disease; disease of hematopoietic system; blood disorder; hematopoietic disease; disorder of hematopoietic system; disease or disorder of hematopoietic system; disease or disorder of haematopoietic system; hematopoietic system disease; hematological disorder; blood dyscrasia; disease of haematopoietic system; haematopoietic disease; haematological disease
Disease Class	3C0Z: Blood-forming organ disease
Definition	A disease involving the hematopoietic system.\|placeholder for lymphoid disease
Disease Hierarchy	DISH7H5I: Human disease DIS9XD9A: Hematologic disease
ICD Code	ICD-11 ICD-11: 3C0Z Expand ICD-11 '3C0Z Expand ICD-10 'III; 'D70-D77; 'D77; 'Q89.9
Disease Identifiers	MONDO ID MONDO_0005570 MESH ID D006402 UMLS CUI C0018939 MedGen ID 5483 Orphanet ID 97992 SNOMED CT ID 191124002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Busulfan	DMXYJ9C	Approved	Small molecular drug	[1]
Fludarabine	DMVRLT7	Approved	Small molecular drug	[2]
Lmw heparin	DMJPD06	Approved	Small molecular drug	[3]
Melphalan	DMOLNHF	Approved	Small molecular drug	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CK0801	DM3WZXO	Phase 1	Cell therapy	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hematological disease agents	DM1K00T	Investigative	Small molecular drug	[6]
HemoTech	DMU5GO8	Investigative	NA	[6]
PN-951	DMXPALT	Investigative	NA	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 15 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HBB	TTM6HK1	Limited	Biomarker	[7]
MTR	TTUTO39	moderate	Biomarker	[8]
SERPINE1	TTTO43N	moderate	Therapeutic	[9]
ABL1	TT6B75U	Strong	Genetic Variation	[10]
ACR	TTAHE2N	Strong	Biomarker	[11]
ALAD	TTJHKYD	Strong	Biomarker	[12]
CYP2J2	TTNE1C7	Strong	Altered Expression	[13]
FABP1	TTIV96N	Strong	Biomarker	[14]
FAS	TT7LTUJ	Strong	Biomarker	[15]
HAX1	TT21BYA	Strong	Biomarker	[16]
HBA2	TTQO71U	Strong	Biomarker	[17]
IL3RA	TTENHJ0	Strong	Altered Expression	[18]
MTHFR	TTQWOU1	Strong	Biomarker	[8]
SERPINA6	TTJL8VG	Strong	Altered Expression	[19]
GSR	TTEP6RV	Definitive	Biomarker	[20]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 DTT(s)

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC7A9	DTP7AEQ	Limited	Biomarker	[21]
SLC4A1	DTB0Q3P	Strong	Biomarker	[22]
SLC25A10	DTJYKDQ	Definitive	Altered Expression	[23]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
TPMT	DEFQ8VO	Strong	Genetic Variation	[24]
------------------------------------------------------------------------------------

This Disease Is Related to 53 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DDX39A	OT0Z6E1K	Limited	Biomarker	[21]
DDX39B	OTEVCFVU	Limited	Biomarker	[21]
HBG2	OT4J48JJ	Limited	Biomarker	[25]
QRSL1	OTJDU2UG	Limited	Biomarker	[26]
GATA1	OTX1R7O1	Disputed	Altered Expression	[27]
FCRL2	OT0RLDOD	moderate	Altered Expression	[28]
GFI1B	OTRDW8YO	moderate	Genetic Variation	[29]
ADAMTS18	OTRMFI04	Strong	Biomarker	[30]
AHSP	OTTHBSUS	Strong	Altered Expression	[31]
AP5Z1	OTXIPLFH	Strong	Genetic Variation	[32]
ASXL1	OTX931AW	Strong	Genetic Variation	[33]
ATF5	OT03QCLM	Strong	Biomarker	[34]
ATRNL1	OTY5JUX2	Strong	Biomarker	[35]
BCL11B	OT8KKCVJ	Strong	Genetic Variation	[36]
BIN1	OTK8O0X8	Strong	Biomarker	[37]
CARD16	OT4NUHWB	Strong	Genetic Variation	[38]
CBFB	OTIAC6W4	Strong	Biomarker	[39]
CKB	OTUCKOTT	Strong	Altered Expression	[40]
DERL1	OTJUS74N	Strong	Genetic Variation	[41]
ENDOU	OTB7OF7Y	Strong	Altered Expression	[42]
EXOSC6	OTAC10N6	Strong	Altered Expression	[42]
FANCC	OTTIDM3P	Strong	Biomarker	[43]
FCRL6	OTLIXQMQ	Strong	Altered Expression	[44]
FUBP1	OT77SC9N	Strong	Biomarker	[45]
FUT1	OTODG57A	Strong	Biomarker	[46]
GAR1	OTA580RX	Strong	Biomarker	[47]
HBG1	OTVL4NSU	Strong	Altered Expression	[48]
HFE	OTDD93KB	Strong	Biomarker	[49]
HLA-E	OTX1CTFB	Strong	Biomarker	[50]
IARS1	OT9WXH5N	Strong	Biomarker	[51]
ICAM4	OT1BI27E	Strong	Genetic Variation	[52]
ICAM5	OTDGGAFH	Strong	Genetic Variation	[52]
KDM2B	OTDMCVW7	Strong	Biomarker	[53]
KLF1	OT1FK08U	Strong	Genetic Variation	[54]
LMAN1	OTYHKDEO	Strong	Genetic Variation	[55]
MCFD2	OTM0XU0U	Strong	Biomarker	[56]
PDLIM3	OTVXQC81	Strong	Biomarker	[35]
PIGA	OT51UWUR	Strong	Genetic Variation	[57]
PMCH	OT3D9SA4	Strong	Altered Expression	[58]
POGLUT1	OTDX7GZD	Strong	Biomarker	[59]
PSMA5	OT38E6Y1	Strong	Genetic Variation	[32]
PSMA7	OTPHI6ST	Strong	Biomarker	[60]
RANBP2	OTFG5CVF	Strong	Biomarker	[61]
RIN1	OTPBROUD	Strong	Biomarker	[37]
RPS19	OTBKGP48	Strong	Genetic Variation	[62]
SAMD9	OTDG48P0	Strong	Genetic Variation	[63]
SAMD9L	OTKEJUCI	Strong	Genetic Variation	[63]
SBDS	OTHDCCIB	Strong	Biomarker	[64]
SSB	OTCCTPBR	Strong	Biomarker	[65]
TRADD	OTBOSJHO	Strong	Genetic Variation	[66]
TSPY1	OTPY57X4	Strong	Genetic Variation	[67]
TSPY3	OTQK3AKI	Strong	Genetic Variation	[67]
CLEC1B	OTO38TRG	Definitive	Altered Expression	[23]
------------------------------------------------------------------------------------


⏷ Show the Full List of 53 DOT(s)

References

1	Busulfan FDA Label
2	Fludarabine FDA Label
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Melphalan FDA Label
5	ClinicalTrials.gov (NCT03773393) A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF). U.S. National Institutes of Health.
6	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7	Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection.J Med Virol. 2019 Jan;91(1):107-114. doi: 10.1002/jmv.25279. Epub 2018 Sep 24.
8	Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.J Pediatr. 2009 May;154(5):688-93. doi: 10.1016/j.jpeds.2008.11.030. Epub 2009 Jan 21.
9	A combined immunostimulatory and immunoinhibitory short interference RNA reduces hypercoagulability in a rat model of acute promyelocytic leukaemia.Thromb Haemost. 2010 Aug;104(2):350-4. doi: 10.1160/TH09-12-0816. Epub 2010 Jun 10.
10	Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.Biochem Pharmacol. 2020 Mar;173:113698. doi: 10.1016/j.bcp.2019.113698. Epub 2019 Nov 7.
11	Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-analysis.Autoimmun Rev. 2018 Mar;17(3):316-322. doi: 10.1016/j.autrev.2018.01.007. Epub 2018 Jan 31.
12	Investigation of delta-aminolevulinic acid dehydratase polymorphism affecting hematopoietic, hepatic and renal toxicity from lead in Han subjects of southwestern China.Acta Physiol Hung. 2014 Mar;101(1):59-66. doi: 10.1556/APhysiol.101.2014.1.7.
13	Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.J Pharmacol Exp Ther. 2011 Feb;336(2):344-55. doi: 10.1124/jpet.110.174805. Epub 2010 Oct 28.
14	Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.Arch Dermatol Res. 2019 Jul;311(5):389-397. doi: 10.1007/s00403-019-01917-w. Epub 2019 Apr 16.
15	Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome.Br J Haematol. 2005 May;129(4):534-8. doi: 10.1111/j.1365-2141.2005.05496.x.
16	Neurodevelopmental abnormalities associated with severe congenital neutropenia due to the R86X mutation in the HAX1 gene.J Med Genet. 2008 Dec;45(12):802-7. doi: 10.1136/jmg.2008.058297. Epub 2008 Jul 8.
17	Complementation of alpha-thalassaemia in alpha-globin knockout mice with a 191 kb transgene containing the human alpha-globin locus.Transgenic Res. 2004 Jun;13(3):235-43. doi: 10.1023/b:trag.0000034627.36174.06.
18	Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.Leuk Res. 2019 Sep;84:106178. doi: 10.1016/j.leukres.2019.106178. Epub 2019 Jun 27.
19	Unexplained high transcortin levels in patients with various hematological disorders and in the relatives: a connection between these high transcortin levels and HLA antigen B12.J Clin Endocrinol Metab. 1980 Mar;50(3):421-6. doi: 10.1210/jcem-50-3-421.
20	Glutathione reductase deficiency in association with sickle cell and thalassaemia genes in Saudi populations.Hum Hered. 1985;35(5):326-32. doi: 10.1159/000153571.
21	Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery.Blood Adv. 2019 Jul 23;3(14):2069-2081. doi: 10.1182/bloodadvances.2019000098.
22	Band 3 HT, a human red-cell variant associated with acanthocytosis and increased anion transport, carries the mutation Pro-868-->Leu in the membrane domain of band 3.Biochem J. 1993 Jul 15;293 ( Pt 2)(Pt 2):317-20. doi: 10.1042/bj2930317.
23	Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy.Thromb Res. 2019 Jun;178:54-58. doi: 10.1016/j.thromres.2019.03.018. Epub 2019 Mar 28.
24	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.Dig Liver Dis. 2016 Dec;48(12):1506-1509. doi: 10.1016/j.dld.2016.08.125. Epub 2016 Sep 1.
25	Stability of postmortem methemoglobin: Artifactual changes caused by storage conditions.Forensic Sci Int. 2018 Feb;283:21-28. doi: 10.1016/j.forsciint.2017.12.009. Epub 2017 Dec 8.
26	The GATA factor revolution in hematology.Blood. 2017 Apr 13;129(15):2092-2102. doi: 10.1182/blood-2016-09-687871. Epub 2017 Feb 8.
27	Regulation of GATA1 levels in erythropoiesis.IUBMB Life. 2020 Jan;72(1):89-105. doi: 10.1002/iub.2192. Epub 2019 Nov 25.
28	FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.Eur J Haematol. 2009 Dec 1;83(6):541-9. doi: 10.1111/j.1600-0609.2009.01328.x. Epub 2009 Aug 4.
29	From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation.Blood. 2015 Dec 10;126(24):2561-9. doi: 10.1182/blood-2015-06-655043. Epub 2015 Oct 7.
30	ADAMTS-18: a metalloproteinase with multiple functions.Front Biosci (Landmark Ed). 2014 Jun 1;19(8):1456-67. doi: 10.2741/4296.
31	alpha-Hemoglobin stabilizing protein is not a suitable marker for a screening test for variant Creutzfeldt-Jakob disease.Transfusion. 2008 Aug;48(8):1616-26. doi: 10.1111/j.1537-2995.2008.01759.x. Epub 2008 May 22.
32	Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases.Hematology. 2008 Oct;13(5):267-75. doi: 10.1179/102453308X343482.
33	Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.Leukemia. 2019 Jan;33(1):191-204. doi: 10.1038/s41375-018-0198-6. Epub 2018 Jul 2.
34	Requirement of activating transcription factor 5 for murine fetal liver erythropoiesis.Br J Haematol. 2020 Feb;188(4):582-585. doi: 10.1111/bjh.16202. Epub 2019 Sep 16.
35	Granulocytes' enzymes as biomarkers of radiotoxicity in individuals occupationally exposed to low-level radiation.J BUON. 2009 Jan-Mar;14(1):85-91.
36	Increased expression of bcl11b leads to chemoresistance accompanied by G1 accumulation.PLoS One. 2010 Sep 2;5(9):e12532. doi: 10.1371/journal.pone.0012532.
37	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.Tumour Biol. 2016 Jan;37(1):217-25. doi: 10.1007/s13277-015-3772-9. Epub 2015 Jul 21.
38	Inherited hematological disorders due to defects in coat protein (COP)II complex.Am J Hematol. 2013 Feb;88(2):135-40. doi: 10.1002/ajh.23292. Epub 2012 Jul 5.
39	Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Adv Exp Med Biol. 2017;962:175-199. doi: 10.1007/978-981-10-3233-2_12.
40	Increased creatine kinase BB activity and CKB mRNA expression in patients with hematologic disorders: relation to methylation status of the CKB promoter.Clin Chim Acta. 2005 Nov;361(1-2):135-40. doi: 10.1016/j.cccn.2005.05.028.
41	Unbalanced 1;7 translocation and therapy-induced hematologic disorders: a possible relationship.Am J Hematol. 1986 Jan;21(1):39-47. doi: 10.1002/ajh.2830210106.
42	Chromosome 12 rearrangement with breakage at the p11 level in hematologic disorders: report of four cases.Cancer Genet Cytogenet. 1985 Feb 15;15(3-4):309-14. doi: 10.1016/0165-4608(85)90175-x.
43	Prenatal diagnosis of Fanconi anemia (Group C) subsequent to abnormal sonographic findings.Prenat Diagn. 2005 Jan;25(1):20-2. doi: 10.1002/pd.1055.
44	FCRL6 receptor: expression and associated proteins.Immunol Lett. 2011 Jan 30;134(2):174-82. doi: 10.1016/j.imlet.2010.09.023. Epub 2010 Oct 7.
45	The master regulator FUBP1: its emerging role in normal cell function and malignant development.Cell Mol Life Sci. 2019 Jan;76(2):259-281. doi: 10.1007/s00018-018-2933-6. Epub 2018 Oct 20.
46	Promises and Challenges in Hematopoietic Stem Cell Gene Therapy.Hum Gene Ther. 2017 Oct;28(10):782-799. doi: 10.1089/hum.2017.141.
47	Zebrafish models for dyskeratosis congenita reveal critical roles of p53 activation contributing to hematopoietic defects through RNA processing.PLoS One. 2012;7(1):e30188. doi: 10.1371/journal.pone.0030188. Epub 2012 Jan 27.
48	Increase in gamma-globin mRNA content in human erythroid cells treated with angelicin analogs.Int J Hematol. 2009 Oct;90(3):318-327. doi: 10.1007/s12185-009-0422-2. Epub 2009 Sep 25.
49	Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.Metallomics. 2017 Jul 19;9(7):852-864. doi: 10.1039/c7mt00039a.
50	The impact of HLA-E polymorphisms on relapse following allogeneic hematopoietic stem cell transplantation.Leuk Res. 2013 May;37(5):516-9. doi: 10.1016/j.leukres.2013.01.011. Epub 2013 Feb 6.
51	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis.Clinics (Sao Paulo). 2018 Oct 11;73(suppl 1):e566s. doi: 10.6061/clinics/2018/e566s.
52	Genetic association study of systemic lupus erythematosus and disease subphenotypes in European populations.Clin Rheumatol. 2016 May;35(5):1161-8. doi: 10.1007/s10067-016-3235-8. Epub 2016 Mar 28.
53	Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.J Virol. 2019 Jun 14;93(13):e00273-19. doi: 10.1128/JVI.00273-19. Print 2019 Jul 1.
54	Krppel-like factor 1: hematologic phenotypes associated with KLF1 gene mutations.Int J Lab Hematol. 2015 May;37 Suppl 1:78-84. doi: 10.1111/ijlh.12356.
55	The COPII pathway and hematologic disease.Blood. 2012 Jul 5;120(1):31-8. doi: 10.1182/blood-2012-01-292086. Epub 2012 May 14.
56	Multiple coagulation factor deficiency protein 2 as a crucial component in metastasis of human oral cancer.Exp Cell Res. 2018 Jul 1;368(1):119-125. doi: 10.1016/j.yexcr.2018.04.021. Epub 2018 Apr 19.
57	Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes.Exp Hematol. 2001 Dec;29(12):1403-9. doi: 10.1016/s0301-472x(01)00746-9.
58	Excessive fluoride consumption increases haematological alteration in subjects with iron deficiency, thalassaemia, and glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.Environ Geochem Health. 2017 Aug;39(4):751-758. doi: 10.1007/s10653-016-9845-x. Epub 2016 Jun 18.
59	hCLP46 regulates U937 cell proliferation via Notch signaling pathway.Biochem Biophys Res Commun. 2011 Apr 29;408(1):84-8. doi: 10.1016/j.bbrc.2011.03.124. Epub 2011 Mar 31.
60	Evaluation of committed and primitive cord blood progenitors after expansion on adipose stromal cells.Cell Tissue Res. 2018 Jun;372(3):523-533. doi: 10.1007/s00441-017-2766-x. Epub 2018 Jan 11.
61	RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.Cancer Genet. 2014 Jan-Feb;207(1-2):40-5. doi: 10.1016/j.cancergen.2013.12.003. Epub 2014 Jan 21.
62	Hypermethylation of 28S ribosomal RNA in -thalassemia trait carriers.Int J Biol Macromol. 2017 Jan;94(Pt A):728-734. doi: 10.1016/j.ijbiomac.2016.10.039. Epub 2016 Oct 17.
63	Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations.Biol Blood Marrow Transplant. 2019 Nov;25(11):2186-2196. doi: 10.1016/j.bbmt.2019.07.007. Epub 2019 Jul 12.
64	Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation.Clin Genet. 2011 May;79(5):448-58. doi: 10.1111/j.1399-0004.2010.01468.x.
65	Glutathione S-transferase genotype and risk of systemic lupus erythematosus in Koreans.Lupus. 2005;14(5):381-4. doi: 10.1191/0961203305lu2100oa.
66	Screening, identification, and functional analysis of three novel missense mutations in the TRADD gene in children with ALL and ALPS.Pediatr Blood Cancer. 2008 Nov;51(5):616-20. doi: 10.1002/pbc.21672.
67	Long-term persistence of hemopoietic chimerism following sex-mismatched bone marrow transplantation.Bone Marrow Transplant. 1997 Dec;20(11):969-73. doi: 10.1038/sj.bmt.1701011.